

Full-length article

Natural product juglone targets three key enzymes from *Helicobacter pylori*: inhibition assay with crystal structure characterization¹Yun-hua KONG, Liang ZHANG, Zheng-yi YANG, Cong HAN, Li-hong HU², Hua-liang JIANG, Xu SHEN²*Drug Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China***Key words**cystathionine γ -synthase; malonyl-CoA:acyl carrier protein transacylase; β -hydroxyacyl-ACP dehydratase; inhibitor type; complex structure**Abbreviation** IC₅₀, the half maximal inhibitory concentration; K_i , the dissociation constant for inhibitor binding. CoA, coenzyme A; ACP, acyl carrier protein transacylase; PDB, Protein Data Bank; HO-HxoDH, D-2-Hydroxyisocaproate dehydrogenase.¹This work was supported by the National Natural Science Foundation of China (No 30525024, 20721003, and 90713046).²Correspondence to Prof Xu SHEN and Prof Li-hong HU.

Phn/Fax 86-21-5080-6918.

E-mail xshen@mail.shnc.ac.cn (Prof Shen)
simmhulh@mail.shnc.ac.cn (Prof Hu)

Received 2008-02-26

Accepted 2008-04-02

doi: 10.1111/j.1745-7254.2008.00808.x

Abstract**Aim:** To investigate the inhibition features of the natural product juglone (5-hydroxy-1,4-naphthoquinone) against the three key enzymes from *Helicobacter pylori* (cystathionine γ -synthase [HpCGS], malonyl-CoA:acyl carrier protein transacylase [HpFabD], and β -hydroxyacyl-ACP dehydratase [HpFabZ]).**Methods:** An enzyme inhibition assay against HpCGS was carried out by using a continuous coupled spectrophotometric assay approach. The inhibition assay of HpFabD was performed based on the α -ketoglutarate dehydrogenase-coupled system, while the inhibition assay for HpFabZ was monitored by detecting the decrease in absorbance at 260 nm with crotonoyl-CoA conversion to β -hydroxybutyryl-CoA. The juglone/FabZ complex crystal was obtained by soaking juglone into the HpFabZ crystal, and the X-ray crystal structure of the complex was analyzed by molecular replacement approach. **Results:** Juglone was shown to potently inhibit HpCGS, HpFabD, and HpFabZ with the half maximal inhibitory concentration IC₅₀ values of 7.0 ± 0.7 , 20 ± 1 , and 30 ± 4 $\mu\text{mol/L}$, respectively. An inhibition-type study indicated that juglone was a non-competitive inhibitor of HpCGS against *O*-succinyl-*L*-homoserine ($K_i = \alpha K_i = 24$ $\mu\text{mol/L}$), an uncompetitive inhibitor of HpFabD against malonyl-CoA ($\alpha K_i = 7.4$ $\mu\text{mol/L}$), and a competitive inhibitor of HpFabZ against crotonoyl-CoA ($K_i = 6.8$ $\mu\text{mol/L}$). Moreover, the crystal structure of the HpFabZ/juglone complex further revealed the essential binding pattern of juglone against HpFabZ at the atomic level. **Conclusion:** HpCGS, HpFabD, and HpFabZ are potential targets of juglone.**Introduction**

Helicobacter pylori (*H. pylori*) is a Gram-negative bacterium associated with a number of human diseases, including gastritis, peptic ulceration, and gastric cancer^[1]. *H. pylori* has been recognized as a pathogenic bacterium that chronically infects approximately 50% of the world's human population^[2]. The rapid infection of *H. pylori* has become a severe threat against human health. Usually, the treatment of *H. pylori* infections involves the administration of a combination of antibiotics and other drugs. However, the overuse and misuse of antibacterial agents have resulted in the generation of antibiotic resistant strains. For example, in the UK, the metronidazole resistance was found by 31.7% against

H. pylori isolates^[3]. Accordingly, the alarming rise of antibiotic resistance among the key bacterial pathogens has strongly stimulated an urgency to develop novel antibacterial agents acting on new drug targets.

The natural product juglone (5-hydroxy-1,4-naphthoquinone; Figure 1A), from the leaves and unripe hulls of the fruits of *Juglans*, was found to demonstrate cytotoxicities when added in cell cultures^[4–6]. Such an effect might result from juglone's involvement in the block of transcription^[7], or K⁺ channel against cell membrane^[8], the inhibition of the peptidyl-prolyl isomerase Pin1^[7,9], or the generation of hydrogen peroxide^[5]. In addition, juglone was found to possess antibacterial properties, including anti-*H. pylori* and




Figure 1. Structures of the 3 natural products. (A) juglone, (B) α -lapachone, and (C) 9-hydroxy- α -lapachone.

antifungal properties^[10]; however, no target information has ever been disclosed.

In the present study, we reported that juglone functions as a multitargeted inhibitor against 3 key enzymes from *H pylori*: cystathionine γ -synthase (HpCGS), malonyl-CoA:acyl carrier protein transacylase (HpFabD), and β -hydroxyacyl-ACP dehydratase (HpFabZ). The analyzed crystal structure of the HpFabZ/juglone complex has further clarified the essential binding feature of juglone against HpFabZ at the atomic level.

It is known that different organisms display distinct spectra of transsulfuration enzymes. Most plants and microbes employ only the forward pathway from cysteine to homocysteine and methionine, and mammals carry out only the reverse transsulfuration, while fungi take up transsulfuration in both directions^[11]. CGS (EC2.5.1.48), encoded by the *metB* gene, is a pyridoxal 5'-phosphate-dependent enzyme responsible for the γ -replacement reaction of an activated form of *L*-homoserine with *L*-cysteine, leading to *L*-cystathionine. For microorganisms, such a reaction is the first step involved in the transsulfuration pathway that converts *L*-cysteine into *L*-homocysteine. Since CGS is absent in non-ruminant animals that require a dietary source of *L*-homocysteine or *L*-methionine^[12,13], it has thus been regarded as an attractive target for antibiotic discovery^[14]. However, the *metB* gene seems to be unessential for *H pylori* growth as reported by Salama *et al*^[15].

Fatty acid biosynthesis (FAS) is an essential pathway for the survival of the organism since fatty acid is the major component of cell membranes and possesses important biological functions. In nature, according to the enzymes involved in the pathway, fatty acid biosynthesis is divided into 2 types: type I (FAS I) and type II (FAS II)^[16-18]. In the FAS I system, which found in animals, the biosynthesis of fatty acid is catalyzed by a multi-enzyme, which is a single polypeptide with 8 distinct domains. However, in the FAS II system, the reactions are carried out by a series of structurally dissociated enzymes as discovered in most bacteria^[16,17]. Due to the large differences between these 2 FAS systems, enzymes like FabD (EC2.3.1.39) and FabZ (EC4.2.1.60) involved in type II fatty acid biosynthesis have been developed as potential

targets for the discovery of antibacterial agents^[17]. FabD catalyzes the transfer of a malonyl moiety from malonyl-CoA to holo-ACP, forming malonyl-ACP as the elongation substrate for the fatty acid biosynthesis^[19-22], while FabZ is the primary dehydratase that participates in the elongation cycles of saturated and unsaturated fatty acid synthesis^[23-26].

It is expected that our current work might help understand the possible antibacterial mechanism for juglone and provide useful structural information for the discovery of an anti-*H pylori* agent by using juglone as a potential multitargeted lead compound.

Materials and methods

Materials *H pylori* strain SS1 was maintained at our institute. The *Escherichia coli* host strain BL21(DE3) was purchased from Stratagene (Germany). The natural product juglone was from the in-house chemical library established in our laboratory. All other chemicals used were of reagent grade or ultra-pure quality.

Expression and purification of HpCGS The HpCGS enzyme was cloned, expressed, and purified according to our recently published work^[27]. Briefly, *HpmetB* was PCR-amplified from *H pylori* SS1 strain genomic DNA and ligated into a pET28b expression vector (Novagen, Germany) and transformed into BL21(DE3) after restriction digestion. The correct clones were expressed at 37°C, and the purified HpCGS enzyme was obtained by using buffer C (20 mmol/L Tris-HCl, pH 8.0, 500 mmol/L NaCl, and 120 mmol/L imidazole) as elution buffer.

Expression and purification of HpFabD The cloning, expression, and purification of HpFabD were performed according to our published description^[28]. The purified HpFabD protein was dialyzed against buffer A (20 mmol/L Tris-HCl, pH 8.0) to remove imidazole.

Expression and purification of HpFabZ The cloning, expression, and purification of HpFabZ were based on our recently published work^[29]. The purified protein was obtained by dialysis against buffer B (20 mmol/L Tris-HCl, pH 8.0, 500 mmol/L NaCl, and 1 mmol/L EDTA).

HpCGS inhibition assay The HpCGS enzyme inhibition assay was carried out according to our recently published study^[27]. The IC₅₀ value of juglone against HpCGS was obtained by fitting the data to a sigmoid dose-response equation using Origin software (OriginLab, Northampton, Massachusetts, USA). Inhibitor type and inhibition constants K_i and K_i were determined by the double-reciprocal (Lineweaver-Burk) plot, and the V_{max} plot and slopes of the lines from the double-reciprocal plot were used as a function of inhibitor concentrations.

HpFabD inhibition assay The HpFabD enzyme inhibition assay was performed based on our reported approach^[28]. To determine the IC₅₀ value of juglone against malonyl-CoA, HpFabD was incubated for 5 min at room temperature with different concentrations of juglone (0–100 μmol/L) in a total volume of 100 μL. To investigate the inhibition mode of juglone against malonyl-CoA, different concentrations of juglone (0, 8, 10 μmol/L) were used, and the reaction was initiated by the addition of malonyl-CoA (5–30 μmol/L). The K_i value was obtained by the Dixon plot.

HpFabZ inhibition assay The enzymatic inhibition assay of the HpFabZ enzyme was monitored by using the reported spectrophotometric method^[26,29,30]. The IC₅₀ value of the inhibitor was estimated by fitting the inhibition data to a dose-dependent curve using a logistic derivative equation^[31]. The inhibitor mechanism was determined in the presence of various inhibitor concentrations (0–50 μmol/L). After 2 h incubation, the reaction was started by the addition of crotonoyl-CoA (10–250 μmol/L). The K_i value was obtained from the Dixon plot and secondary plots.

Crystallization and data collection The crystallization of the HpFabZ/juglone complex was carried out according to our previous work^[30]. The purified HpFabZ enzyme in 20 mmol/L Tris-HCl (pH 9.0) and 500 mmol/L NaCl was concentrated to ~10 μg/mL. For crystallization, 1 μL of the enzyme was mixed with an equal volume of the reservoir solution containing 2 mol/L sodium formate and 0.1 mol/L sodium acetate trihydrate at pH 3.6–5.6, and benzamidine-HCl was added to a final concentration of 2% (w/v). The mixture was equilibrated against 500 μL of the reservoir solution at 277K by the hanging-drop vapor-diffusion method. Crystals of dimensions 0.5×0.3×0.3 mm³ were obtained after 7 d. Juglone was added to the original drop to a final concentration of ~20 mmol/L, and the crystals were soaked for 24 h.

Diffraction data were collected at 100K using CuKα X-ray with a Rigaku R-AXIS IV⁺⁺ image plate (Rigaku Corp, Tokyo, Japan). Before the crystals were flash-frozen in liquid nitrogen, the drop was dehydrated against 500 μL reservoir solution containing 4 mol/L sodium formate for 24 h. The data were processed using HKL2000^[32]. The crystallographic statistics are summarized in Table 1. The structure was solved by the molecular replacement approach using the crystal structure of HpFabZ as the search model and refined by the program CNS^[33]. Electron density interpretation and model building were performed using the computer graphics program “coot”^[34].

Results

Juglone is a multitargeted inhibitor against CGS, FabD,

Table 1. Summary of diffraction data and structure refinement statistics.

Structure	Complex
Data collection	
Space group	P2 ₁ 2 ₁
Cell dimensions (Å)	
a	73.9826
b	100.3689
c	186.236
α	90
β	90
γ	90
Wavelength	1.5418
Resolution(Å) ¹	50.00-2.40 (2.53-2.40)
R _{sym} ²	0.106(0.301)
I/σI	13.4(4.1)
Completeness (%)	99.8(99.9)
Redundancy	5.7(5.4)
Refinement	
N _o reflections	55018(7903)
R _{work} /R _{free} ³	0.192/0.228
N _o atoms	
Protein	7289
Benzamidine-HCl	63
Cl ⁻ ions	6
Water molecules	492
Compound	26
B-factors	
Protein	20.344
Benzamidine-HCl	20.71
Cl ⁻ ions	38.2
Water molecules	25.988
Compound	46.33
Root mean square deviations	
Bond lengths (Å)	0.007
Bond angles (°)	1.4

¹Numbers in parentheses represent statistics in highest resolution shell.

$$^2R_{\text{sym}} = \frac{\sum_h \sum_i |I_{hi} - \langle I_h \rangle|}{\sum_h \sum_i I_{hi}}$$

$$^3R_{\text{work}} = \frac{\sum_h |F_{\text{oh}} - F_{\text{ch}}|}{\sum_h F_{\text{oh}}}$$

and FabZ enzymes Inhibition against CGS enzyme as evaluated from the enzymatic assay, the natural product juglone was identified to show strong inhibitory activity against HpCGS with an IC₅₀ of 7.0±0.7 μmol/L (Table 2). In a separate control experiment by directly using 2 mmol/L α-ketobutyrate as the substrate, juglone showed no inhibition activity against D-2-hydroxyisocaproate dehydrogenase (HO-HxoDH) at its concentration, even up to 50 μmol/L, further confirming that juglone is a HpCGS inhibitor. The Lineweaver-Burk plot-based analysis indicated that juglone

Table 2. Inhibition data of juglone against CGS, FabD, and FabZ enzymes from *H pylori*.

Enzyme	Inhibition mode	IC ₅₀ (μmol/L)	K _i (μmol/L)	αK _i (μmol/L)
HpCGS	Non-competitive	7.0±0.7	24	24
HpFabD	Uncompetitive	20±1	-	7.4
HpFabZ	Competitive	30±4	6.8	-

prevented the binding of *O*-succinyl-*L*-homoserine (*L*-OSHS) to HpCGS in a non-competitive fashion (Figure 2A), and the inhibition constants K_i of 24 μmol/L and αK_i of 24 μmol/L (Table 2) were determined from the Dixon plot and secondary plots.

Inhibition against HpFabD As indicated in Table 2, juglone could inhibit HpFabD with an IC₅₀ against malonyl-CoA at 20±1 μmol/L as a non-competitive inhibitor (Figure 2B). The αK_i value of 7.4 μmol/L (Table 2) was thereby obtained by the Dixon plot.

Inhibition against HpFabZ As indicated in Figure 2C, besides targeting CGS and FabD, juglone was also detected as a competitive inhibitor against HpFabZ by an IC₅₀ of 30±4 μmol/L (Table 2) with respect to the substrate crotonyl-CoA. The apparent value of K_m at different inhibitor concentrations as a function of the inhibitor concentration.

Crystal structure analysis of the HpFabZ/juglone complex In order to gain the essential inhibition mechanism at the atomic level for juglone against these 3 enzymes, we tried crystallizing the enzymes in complex with juglone and succeeded in obtaining the crystal of the HpFabZ/juglone complex, which was well determined against 2.4 Å level data (PDB code: 3B7J, Figure 3 and Table 1). As shown in the analyzed complex structure, juglone binds to HpFabZ in 2 binding models similar to our previous binding model for HpFabZ binding to the inhibitor^[30] (Figure 4). In model A, juglone fits into the groove around the entrance (Figure 4A) and locates between the phenol ring of Tyr100 and the pyrrolidine ring of Pro112', forming a sandwich structure (the prime indicates a residue from the other subunit in the dimer). As shown in Figure 4B, the carbonyl oxygen of juglone forms H-bonds with the nearby water chain, which also forms H-bonds with the back bone carbonyl oxygen atoms of Phe65', Ile111', Val 146', and Phe101, as well as the back bone nitrogen of Val113'. In model B, juglone entered into the middle of the tunnel near the active site of HpFabZ (His58 and Glu72'; Figure 4C) and was stabilized via the hydrophobic interactions between residues Leu21, His23, Ala75, Phe83, Ile98, Val 99, and Phe59'. At this stage, the carbonyl oxygen of juglone




Figure 2. Inhibition mode analysis of juglone against HpCGS, HpFabD, and HpFabZ. (A) Representative plot of 1/v vs 1/L-OSHS for HpCGS at different inhibitor concentrations. Plot indicates that juglone is a non-competitive inhibitor against HpCGS. (B) Representative plot of 1/v vs 1/malonyl-CoA for HpFabD at different inhibitor concentrations. Juglone was detected as an uncompetitive inhibitor for HpFabD against malonyl-CoA. (C) Representative plot of 1/v vs 1/crotonyl-CoA for HpFabZ at different inhibitor concentrations. Juglone prevents the binding of crotonyl-CoA to HpFabZ in a competitive fashion.




Figure 3. Stereo view of the omitted electron density map contoured at 1.0σ around juglone. Monomers A/B are yellow/magenta, monomers C/D are blue/orange, and juglone is salmon




Figure 4. Crystal structure of the HpFabZ/juglone complex. (A) binding model A of juglone in the HpFabZ active tunnel. Electrostatic surface of the active tunnel is rendered by a color ramp from red to blue. Critical residues and water molecules that interact with juglone are shown. Dimer A/B is yellow/magenta, and dimer C/D is blue/orange; juglone is salmon. Water and chlorine atoms are shown as red and green spheres. Oxygen and nitrogen are red and blue, respectively. (B) H-bond network around juglone in binding model A. H-bonds are shown as yellow dashes. Residues around juglone are labeled. (C) binding model B of juglone in the active tunnel. (D) H-bond network around juglone in binding model B. Image produced by Pymol^[40].

could form H-bonds with the nearby water chain that also forms H-bonds with the back bone carbonyl oxygens of

Ala75, the Nε2 of His 23 and His58', and Oε1 and Oε2 of Glu72 (Figure 4D).

Discussion

Recently, the rapid infection of *H pylori* has become a severe threat to human health, and the discovery of new, effective drugs has attracted more and more attention. Many antibacterial agents used for standard pathogens in clinics are subject to high-level resistance resulting from single-step mutations from target enzymes, whereas multitargeted agents might display low potential for rapid endogenous resistance development in pathogenic bacteria^[35].

It is reported that juglone could strongly inhibit *H pylori* growth at a low MIC of $1.6 \mu\text{g/mL}$ ^[36,37], although no acting target information has ever been disclosed. In the current work, we discovered that juglone functions as a multitargeted inhibitor against 3 key enzymes, HpCGS, HpFabD, and HpFabZ, which provides some clues for the inhibitory mechanism underlying juglone's anti-*H pylori* activity.

In the last 10 years, many CGS and FabZ inhibitors have been discovered. However, most of the inhibitors are single-targeted, except some flavonoid derivatives (luteolin and (-)-catechin gallate), which were reported to inhibit *Plasmodium falciparum* by acting as multitargeted inhibitors against FabG, FabZ, and FabI of *Plasmodium falciparum*^[38].

In our previous work^[27], we reported that the natural products α -lapachone and 9-hydroxy- α -lapachone demonstrated inhibitory activities against HpCGS. Considering the structure similarity between these 2 compounds and juglone, each of them contains a common quinone group (Figure 1). Although the natural products α -lapachone and 9-hydroxy- α -lapachone exhibited no inhibition activities against HpFabD and HpFabZ, as evaluated by the inhibition assay, the quinone group seemed to have some links to the CGS enzyme inhibition.

The natural product corytuberine was our first published HpFabD inhibitor^[28]. Similar to corytuberine, juglone functions in an uncompetitive mode to inhibit HpFabD (Table 2). In addition, the inhibition study indicated that juglone was a competitive inhibitor of HpFabZ, suggesting that juglone may interfere with the binding of substrate crotonoyl-CoA, which could further be proved by the inhibitor binding manner in the complex structure. The binding affinity of juglone to HpFabZ ($K_i=6.8 \mu\text{mol/L}$) was higher than that to HpCGS or HpFabD, which might be attributed to the competitive inhibition type of juglone against HpFabZ.

Previously^[30], we reported 2 crystal structures of HpFabZ in complex with 2 small molecular inhibitors, and 2 binding models of an inhibitor against HpFabZ were supposed. In

binding model A, the inhibitor is sandwiched between the phenol ring of Tyr100 and the pyrrolidine ring of Pro112', and forms a π - π interaction. In binding model B, the inhibitor locates into the middle of the tunnel via hydrophobic interactions. Juglone also fits in these 2 models (Figure 3), of which the position in model A is corresponding to the groove around the entrance, and the position in model B is corresponding to the active site of the tunnel near the catalytic residues His58 and Glu72, in agreement with the competitive inhibitory properties of juglone against HpFabZ determined by the inhibition type study. However, in comparison with this previous HpFabZ-inhibitor crystal structure analysis, 2 major differences are found for juglone binding to HpFabZ. First, in the binding model of HpFabZ/juglone, besides the π - π or hydrophobic interactions, juglone was also stabilized by the H-bonds formed by the water chain between the enzyme and juglone. The other major difference is that in binding model B, juglone is inserted deeper to the tunnel (near Phe83) with a more suitable hydrophobic environment for the binding, different from the previously reported HpFabZ-inhibitor binding case, where the inhibitor formed a sandwich-like conformation with Ile98 and His59' of HpFabZ. It is thus expected that the information based on the HpFabZ/juglone complex would be useful for structure-guided drug design which might provide novel competent HpFabZ inhibitors.

In summary, in the present study, we have discovered that the natural product juglone is a multitargeted inhibitor against 3 key enzymes CGS, FabD, and FabZ from *H. pylori*. The obtained crystal structural data for the HpFabZ/juglone complex has further clarified the essential binding feature of juglone against HpFabZ at the atomic level. Although further experiments, such as a cell labeling assay^[39], are needed to determine whether or not these 3 enzymes are targets responsible for juglone's anti-*H. pylori* activity, juglone could hopefully serve as a potent lead compound for further inhibitory development as stated, and that the multi-targeted inhibitors might provide low potential for rapid endogenous resistance development^[35].

Author contribution

Prof Xu SHEN, Prof Hua-liang JIANG and Prof Li-hong HU designed the research. Yun-hua KONG performed the research, analyzed data and wrote the paper. Liang ZHANG determined the complex structure. Zhen-yi YANG synthesized the compound and Cong HAN contributed the platform for determining MIC values against Hp.

References

1 Dubreuil JD, Giudice GD, Rappuoli R. Helicobacter pylori inter-

actions with host serum and extracellular matrix proteins: potential role in the infectious process. *Microbiol Mol Biol Rev* 2002; 66: 617-29.

2 Cover TL, Blaser MJ. Helicobacter pylori infection, a paradigm for chronic mucosal inflammation: pathogenesis and implications for eradication and prevention. *Adv Intern Med* 1996; 41: 85-117.

3 Cameron EA, Powell KU, Baldwin L, Jones P, Bell GD, Williams SG. Helicobacter pylori: antibiotic resistance and eradication rates in Suffolk, UK, 1991-2001. *J Med Microbiol* 2004; 53: 535-8.

4 Paulsen MT, Ljungman M. The natural toxin juglone causes degradation of p53 and induces rapid H2AX phosphorylation and cell death in human fibroblasts. *Toxicol Appl Pharmacol* 2005; 209: 1-9.

5 Inbaraj JJ, Chignell CF. Cytotoxic action of juglone and plumbagin: a mechanistic study using HaCaT keratinocytes. *Chem Res Toxicol* 2004; 17: 55-62.

6 Rippmann JF, Hobbie S, Daiber C, Guilliard B, Bauer M, Birk J, *et al*. Phosphorylation-dependent proline isomerization catalyzed by Pin1 is essential for tumor cell survival and entry into mitosis. *Cell Growth Differ* 2000; 11: 409-16.

7 Chao SH, Greenleaf AL, Price DH. Juglone, an inhibitor of the peptidyl-prolyl isomerase Pin1, also directly blocks transcription. *Nucleic Acids Res* 2001; 29: 767-73.

8 Varga Z, Bene L, Pieri C, Damjanovich S, Gaspar R. The effect of juglone on the membrane potential and whole-cell K⁺ currents of human lymphocytes. *Biochem Biophys Res Commun* 1996; 218: 828-32.

9 Hennig L, Christner C, Kipping M, Schelbert B, Rucknagel KP, Grabley S, *et al*. Selective inactivation of parvulin-like peptidyl-prolyl cis/trans isomerases by juglone. *Biochemistry* 1998; 37: 5953-60.

10 Alice MC, Tannis MJ, Charles DH. Antimicrobial activity of juglone. *Phytotherapy Research* 1990; 4: 11-4.

11 Clausen T, Huber R, Prade L, Wahl MC, Messerschmidt A. Crystal structure of Escherichia coli cystathionine gamma-synthase at 1.5 Å resolution. *EMBO J* 1998; 17: 6827-38.

12 Soda K. Microbial sulfur amino acids: an overview. *Methods Enzymol* 1987; 143: 453-9.

13 Aitken SM, Kim DH, Kirsch JF. Escherichia coli cystathionine gamma-synthase does not obey ping-pong kinetics. Novel continuous assays for the elimination and substitution reactions. *Biochemistry* 2003; 42: 11297-306.

14 Wahl MC, Huber R, Prade L, Marinkovic S, Messerschmidt A, Clausen T. Cloning, purification, crystallization, and preliminary X-ray diffraction analysis of cystathionine gamma-synthase from *E. coli*. *FEBS Lett* 1997; 414: 492-6.

15 Salama NR, Shepherd B, Falkow S. Global transposon mutagenesis and essential gene analysis of Helicobacter pylori. *J Bacteriol* 2004; 186: 7926-35.

16 Campbell JW, Cronan JE. Bacterial fatty acid biosynthesis: targets for antibacterial drug discovery. *Annu Rev Microbiol* 2001; 55: 305-32.

17 White SW, Zheng J, Zhang YM, Rock CO. The structure biology of type II fatty acid biosynthesis. *Annu Rev Biochemistry* 2005; 74: 791-831.

18 Magnuson K, Jackowski S, Rock CO, Cronan JE. Regulation of

- fatty acid biosynthesis in *Escherichia coli*. *Microbiol Rev* 1993; 57: 522–42.
- 19 Williamson IP, Wakil SJ. Studies on the mechanism of fatty acid synthesis. XVII. Preparation and general properties of acetyl coenzyme A and malonyl coenzyme A-acyl carrier protein transacylases. *J Biol Chem* 1966; 241: 2326–32.
 - 20 Ruch FE, Vagelos PR. The isolation and general properties of *Escherichia coli* malonyl coenzyme A-acyl carrier protein transacylase. *J Biol Chem* 1973; 248: 8086–94.
 - 21 Verwoert II, Verbree EC, van der Linden KH, Nijkamp HJ, Stuitje AR. Cloning, nucleotide sequence, and expression of the *Escherichia coli* fabD gene, encoding malonyl coenzyme A-acyl carrier protein transacylase. *J Bacteriol* 1992; 174: 2851–7.
 - 22 Kutchna AJ, Hoang TT, Schweizer HP. Characterization of a *Pseudomonas aeruginosa* fatty acid biosynthetic gene cluster: purification of acyl carrier protein (ACP) and malonyl-coenzyme A:ACP transacylase (FabD). *J Bacteriol* 1999; 181: 5498–504.
 - 23 Mohan S, Kelly TM, Eveland SS, Raetz CR, Anderson MS. An *Escherichia coli* gene (FabZ) encoding (3R)-hydroxymyristoyl acyl carrier protein dehydrase. Relation to fabA and suppression of mutations in lipid A biosynthesis. *J Biol Chem* 1994; 269: 32 896–903.
 - 24 Heath RJ, Rock CO. Roles of the FabA and FabZ beta-hydroxyacyl-acyl carrier protein dehydratases in *Escherichia coli* fatty acid biosynthesis. *J Biol Chem* 1996; 271: 27 795–801.
 - 25 Pillai S, Rajagopal C, Kapoor M, Kumar G, Gupta A, Surolia N. Functional characterization of beta-ketoacyl-ACP reductase (FabG) from *Plasmodium falciparum*. *Biochem Biophys Res Commun* 2003; 303: 387–92.
 - 26 Sharma SK, Kapoor M, Ramya TN, Kumar S, Kumar G, Modak R, *et al*. Identification, characterization, and inhibition of *Plasmodium falciparum* beta-hydroxyacyl-acyl carrier protein dehydratase (FabZ). *J Biol Chem* 2003; 278: 45 661–71.
 - 27 Kong YH, Wu DL, Bai HY, Han C, Chen J, Chen LL, *et al*. Enzymatic characterization and inhibitor discovery of a new cystathionine γ -synthase (CGS) from *Helicobacter pylori*. *J Biochem (Tokyo)* 2008; 143:59–68
 - 28 Liu WZ, Han C, Hu LH, Chen KX, Shen X, Jiang HL. Characterization and inhibitor discovery of one novel malonyl-CoA: acyl carrier protein transacylase (MCAT) from *Helicobacter pylori*. *FEBS Lett* 2006; 580: 697–702.
 - 29 Liu WZ, Luo C, Han C, Peng SY, Yang Y, Yue J, *et al*. A new beta-hydroxyacyl-acyl carrier protein dehydratase (FabZ) from *Helicobacter pylori*: molecular cloning, enzymatic characterization, and structural modeling. *Biochem Biophys Res Commun* 2005; 333: 1078–86.
 - 30 Zhang L, Liu WZ, Hu TC, Du L, Luo C, Chen KX, *et al*. Structural basis for catalytic and inhibitory mechanisms of beta-hydroxyacyl-acyl carrier protein dehydratase (FabZ). *J Biol Chem* 2008; 283: 5370–9.
 - 31 Chen LL, Gui CS, Luo XM, Yang QG, Gunther S, Scandella E, *et al*. Cinanserin is an inhibitor of the 3C-like proteinase of severe acute respiratory syndrome coronavirus and strongly reduces virus replication in vitro. *J Virol* 2005; 79: 7095–103.
 - 32 Otwinowski Z, Minor W. *Methods in Enzymology* 1997; 276: 307–26.
 - 33 Brunger AT, Adams PD, Clore GM, DeLano W L, Gros P, Grosse-Kunstleve, *et al*. Crystallography and NMR system: a new software suite for macromolecular structure determination. *Acta Crystallogr D Biol Crystallogr* 1998; 54: 905–21.
 - 34 Emsley P, Cowtan K. Coot: model-building tools for molecular graphics. *Acta Crystallogr D Biol Crystallogr* 2004; 60: 2126–32.
 - 35 Silver LL. Multi-targeting by monotherapeutic antibacterials. *Nat Rev Drug Discov* 2007; 6: 41–55.
 - 36 Inatsu S, Ohsaki A, Nagata K. Idebenone acts against growth of *Helicobacter pylori* by inhibiting its respiration. *Antimicrob Agents Chemother* 2006; 50: 2237–9.
 - 37 Park BS, Lee HK, Lee SE, Piao XL, Takeoka GR, Wong RY, *et al*. Antibacterial activity of *Tabebuia impetiginosa* Martius ex DC (Taheebo) against *Helicobacter pylori*. *J Ethnopharmacol* 2006; 105: 255–62.
 - 38 Tasdemir D, Lack G, Brun R, Ruedi P, Scapozza L, Perozzo R. Inhibition of *Plasmodium falciparum* fatty acid biosynthesis: evaluation of FabG, FabZ, and FabI as drug targets for flavonoids. *J Med Chem* 2006; 49: 3345–53.
 - 39 Wang J, Soisson SM, Young K, Shoop W, Kodali S, Galgocsi A, *et al*. Platensimycin is a selective FabF inhibitor with potent anti-biotic properties. *Nature* 2006; 441: 358–61.
 - 40 Delanoue WL. *The PyMOL Molecular Graphics System*. San Carlos, CA: DelanoScientific, 2000.